Average wholesale price of temozolomide following FDA approval could be $300 per day for a 200 mg/m2 dose. A post-hoc economic analysis of a Phase III trial in metastatic melanoma presented at the American Society of Clinical Oncology used the AWP figure to determine that Temodal would have a mean cost of $6,902 per patient compared to $3,697 per patient for treatment with DTIC. FDA's Oncologic Drugs Advisory Committee recommended against approval of the drug for metastatic melanoma and glioblastoma multiforme in January. Temodal became "approvable" for the treatment of anaplastic astrocytoma Feb. 2 ("The Pink Sheet" March 15, p.15)
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth